Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio is a clinical stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with unmet medical needs. The company's flagship product candidate, tinlarebant, is intended for the treatment of geographic atrophy (GA) and Stargardt disease type 1 (STGD1) and has a potential revenue of multiple billions of dollars. With its ongoing NDA submission and rolling submission process, the company is on track to potentially become the first-ever approved therapy for STGD1 and expects a swift US commercial launch after FDA approval. Additionally, Belite Bio's product pipeline includes a compound for the treatment of metabolic diseases with a huge market potential. With a promising financial outlook and multiple potential revenue streams, Belite Bio is a promising stock for investors looking for growth opportunities in the pharmaceutical industry.

Bears say

Belite Bio is facing several challenges that have caused a decline in investor confidence. Despite their promising product pipeline, the company has not yet generated significant revenue and is incurring a significant cost of sales. This, combined with the limited market for their targeted diseases, may hinder their ability to turn a profit in the near future.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $203.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $203.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.